Estriol
- Generic Name
- Estriol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H24O3
- CAS Number
- 50-27-1
- Unique Ingredient Identifier
- FB33469R8E
- Background
A hydroxylated metabolite of estradiol or estrone that has a hydroxyl group at C3-beta, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen. During pregnancy, large amount of estriol is produced by the placenta. Isomers with inversion of the hydroxyl group or groups are called epiestriol. Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada. It is however available in the United States by prescription filled only by compounding pharmacies. It has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes.
- Indication
Used as a test to determine the general health of an unborn fetus.
- Associated Conditions
- Cervicitis, Menopausal and Postmenopausal Disorders, Hypoestrogenism
- Associated Therapies
- Estrogen Replacement Therapy
North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)
- Conditions
- Interventions
- First Posted Date
- 2011-08-02
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- James Gossage
- Target Recruit Count
- 123
- Registration Number
- NCT01408030
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Georgia Regents University, Augusta, Georgia, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
Topical Estriol for Vaginal Health
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2011-03-04
- Lead Sponsor
- Gynuity Health Projects
- Target Recruit Count
- 104
- Registration Number
- NCT00908570
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸Harbor-UCLA Medical Center, Los Angeles, California, United States
A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis
- Conditions
- Interventions
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2017-11-13
- Lead Sponsor
- Maire Mac Bride
- Target Recruit Count
- 63
- Registration Number
- NCT00816556
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)
- Conditions
- Interventions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 158
- Registration Number
- NCT00451204
- Locations
- 🇺🇸
Western Institute for Biomedical Research, Salt Lake City, Utah, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
🇺🇸Dartmouth Medical School, Lebanon, New Hampshire, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.